JP7704690B2 - 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム - Google Patents

抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム Download PDF

Info

Publication number
JP7704690B2
JP7704690B2 JP2021578078A JP2021578078A JP7704690B2 JP 7704690 B2 JP7704690 B2 JP 7704690B2 JP 2021578078 A JP2021578078 A JP 2021578078A JP 2021578078 A JP2021578078 A JP 2021578078A JP 7704690 B2 JP7704690 B2 JP 7704690B2
Authority
JP
Japan
Prior art keywords
pharma
less
acceptable salt
compound
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021578078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538898A (ja
JP2022538898A5 (https=
Inventor
ロンロン ジャン，
ヴァイシャリ ディクシット，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2022538898A publication Critical patent/JP2022538898A/ja
Publication of JP2022538898A5 publication Critical patent/JP2022538898A5/ja
Application granted granted Critical
Publication of JP7704690B2 publication Critical patent/JP7704690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021578078A 2019-07-01 2020-07-01 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム Active JP7704690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869389P 2019-07-01 2019-07-01
US62/869,389 2019-07-01
PCT/US2020/040515 WO2021003279A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound e7766

Publications (3)

Publication Number Publication Date
JP2022538898A JP2022538898A (ja) 2022-09-06
JP2022538898A5 JP2022538898A5 (https=) 2023-07-11
JP7704690B2 true JP7704690B2 (ja) 2025-07-08

Family

ID=71895194

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021578078A Active JP7704690B2 (ja) 2019-07-01 2020-07-01 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム

Country Status (10)

Country Link
US (1) US12564600B2 (https=)
EP (1) EP3993809B1 (https=)
JP (1) JP7704690B2 (https=)
KR (1) KR20220029717A (https=)
CN (1) CN114599374A (https=)
AU (1) AU2020300543A1 (https=)
BR (1) BR112021026876A2 (https=)
CA (1) CA3145824A1 (https=)
MX (1) MX2022000052A (https=)
WO (1) WO2021003279A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024533394A (ja) 2021-09-09 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｓｔｉｎｇアゴニストのバイオマーカー及びその使用方法
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516423A (ja) 2012-05-07 2015-06-11 ノバルティス アーゲー アリスポリビルによる薬物動態の調節
WO2018152450A1 (en) 2017-02-17 2018-08-23 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides compounds for the treatment of cancer
JP2019052192A (ja) 2017-06-30 2019-04-04 興和株式会社 医薬
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER
JP2019512233A (ja) 2016-03-10 2019-05-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) * 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
PL3265565T3 (pl) 2015-03-04 2021-01-25 Board Of Regents, The University Of Texas System Sposoby leczenia nowotworu z hemizygotyczną utratą tp53

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516423A (ja) 2012-05-07 2015-06-11 ノバルティス アーゲー アリスポリビルによる薬物動態の調節
JP2019512233A (ja) 2016-03-10 2019-05-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
WO2018152450A1 (en) 2017-02-17 2018-08-23 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides compounds for the treatment of cancer
JP2019052192A (ja) 2017-06-30 2019-04-04 興和株式会社 医薬
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER

Also Published As

Publication number Publication date
AU2020300543A1 (en) 2022-02-24
JP2022538898A (ja) 2022-09-06
CN114599374A (zh) 2022-06-07
MX2022000052A (es) 2022-04-06
EP3993809B1 (en) 2024-10-09
EP3993809A1 (en) 2022-05-11
BR112021026876A2 (pt) 2022-02-22
KR20220029717A (ko) 2022-03-08
US12564600B2 (en) 2026-03-03
WO2021003279A1 (en) 2021-01-07
US20220304982A1 (en) 2022-09-29
CA3145824A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7190425B2 (ja) 肝細胞癌の治療のための併用療法
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
JP7704690B2 (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
JP2018515587A (ja) 医薬組成物およびその使用
RU2820595C2 (ru) Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250414

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250626

R150 Certificate of patent or registration of utility model

Ref document number: 7704690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150